Jobs at Notable Labs

Changing the way cancer is treated is our personal mission, which starts with putting patients first. We’ve developed an individualized laboratory testing service for cancer patients and their doctors. We screen thousands of FDA-approved drugs against the patients own cancer cells to identify drug combinations that can be immediately prescribed by their doctor without a clinical trial. By repositioning treatment as a patient-centered service we can unlock the power of modern data science and laboratory automation to achieve the promise of combination therapy and personalized medicine.

Our investors include Founders Fund, First Round Capital, Y Combinator, several prominent angels and seed-stage funds, and Accelerate Brain Cancer Cure, a venture philanthropy firm founded by Steve Case. We have offices and a laboratory in San Francisco’s SoMa district.

Technology:

We’ve developed a high throughput robotic testing platform that uses a patient’s live tumor cells to predict the safest and most effective treatment combinations. We employ an ex vivo assay to survey thousands of drug combination options. To ensure our translational system is predictive we’ve created a proprietary method to mimic the microenvironment of the human body. Our drug panel includes all approved chemotherapies and targeted agents, as well as generic non-oncology drugs that have published anti-neoplastic evidence.

We prioritize the safest combinations from our viability assay by estimating a therapeutic index. Successful hits are counter-screened against normal human cells to determine a customized, relative drug scoring system for each patient. The end result of our process is a CLIA certified report which prioritizes therapeutic options that could be used by the physician and patient.

What We're Building

Clinical lab service: We help doctors identify personalized combinations of FDA-approved treatments for their cancer patients. Focusing on individual patients + existing treatments, we’re discovering new uses of drugs and defining mechanisms underlying cancer progression and drug resistance. Using robotic + modern data science, we’re building a scalable, iterative model that will turn individual treatment selection into a data problem.

R&D platform: The clinical lab service acts as a funnel to acquire primary patient samples for biopharma partnerships. Using our automated, multi-parametric drug screening research platform, collaborators can assay the biological impact of compounds on primary cells in a physiologically relevant environment. This platform helps our partners stratify patients, de-risking drug development and increasing their probability of success.